Motus GI reports net revenue decrease in third quarter, clinical trial enrollment

Motus GI reported a net loss of approximately $5.2 million in its third quarter, or $0.33 per share.
For the nine months ended in September, Motus GI reported a net loss of approximately $16.7 million, or $1.13 per share.
“We have made significant progress in recent months to ensure the Company is positioned for a successful commercial launch of the Pure-Vu System in 2019,” Tim Moran, CEO of Motus GI, said in a company press release. “I firmly believe that a critical part of that process includes having the right team in place, not only at the executive level but across our

Source link

Related posts

Subcutaneous vedolizumab shows promise for ulcerative colitis


Fibrosis diagnostic accuracy higher in MRE vs. transient elastography


Ver(s)ifying the efficacy of vedolizumab therapy on mucosal healing in Crohn’s disease patients


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy